Medipost secured $140 million to support commercialization and regulatory filings for its allogeneic stem cell therapy in the U.S. and Japan. The Seoul‑area company will use the funds to expand its Cambridge, MA subsidiary and to navigate clinical development, manufacturing scale‑up and regulatory pathways for a therapy that has been approved in South Korea since 2012. Medipost emphasized its goal of leveraging prior approvals and existing data to accelerate clinical programs and market access in Western markets while establishing local infrastructure and partnerships.